“The last time I crossed paths with Kevin Judice, he was helping Jeff Stein launch San Diego-based Cidara Therapeutics, an antibiotics developer that lay well outside the perimeters of Judice’s home base in the Bay Area. Now Judice, a Genentech veteran and longtime biotech entrepreneur on the West Coast, is gearing up DiCE Molecules, a spinout from a much closer campus at Stanford that’s jumping into the spotlight today with the help of a collaboration with Sanofi’s ($SNY) Sunrise team that starts with $50 million in early-stage cash and support, with the potential to add billions more for a successful lineup of programs.
DiCE is the brainchild of Pehr Harbury, a Stanford professor and biochemist–and MacArthur “genius” award winner–who’s been constructing the building blocks of a platform technology, which is exactly Sanofi’s sweet spot for cutting-edge deals.” Full article
- Bay Area Startup DiCE Molecules Inks Small Molecule Deal Worth Up to $2.3 Billion with Sanofi (BioSpace)
- Sanofi Strikes $2.3 Billion Deal With DiCE Molecules (Fortune/Reuters)
- Sanofi and DiCE Molecules Announce Research Collaboration to Discover Potential Therapeutics Based on Unique Small Molecule Discovery Platform (press release)